S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in
patients at high risk of CV events such as patients suffering from nonrheumatic atrial
fibrillation.